Oppenheimer Co Inc Lowers stake in Gilead Sciences (GILD)

Gilead Sciences (GILD) : Oppenheimer Co Inc reduced its stake in Gilead Sciences by 0.79% during the most recent quarter end. The investment management company now holds a total of 1,184,501 shares of Gilead Sciences which is valued at $104,484,833 after selling 9,478 shares in Gilead Sciences , the firm said in a disclosure report filed with the SEC on Apr 26, 2016.Gilead Sciences makes up approximately 3.14% of Oppenheimer Co Inc’s portfolio.

Gilead Sciences opened for trading at $88.7 and hit $89.45 on the upside on Monday, eventually ending the session at $89, with a gain of 0.90% or 0.79 points. The heightened volatility saw the trading volume jump to 1,35,24,049 shares. Company has a market cap of $121,649 M.

Other Hedge Funds, Including , Mu Investments Ltd. boosted its stake in GILD in the latest quarter, The investment management firm added 20 additional shares and now holds a total of 7,370 shares of Gilead Sciences which is valued at $650,108. Gilead Sciences makes up approx 0.41% of Mu Investments Ltd.’s portfolio. Quantitative Systematic Strategies added GILD to its portfolio by purchasing 8,159 company shares during the most recent quarter which is valued at $831,647. Gilead Sciences makes up approx 0.31% of Quantitative Systematic Strategies’s portfolio.Capital Impact Advisors reduced its stake in GILD by selling 5,232 shares or 23.27% in the most recent quarter. The Hedge Fund company now holds 17,255 shares of GILD which is valued at $1,695,994. Gilead Sciences makes up approx 0.80% of Capital Impact Advisors’s portfolio.Bkd Wealth Advisors reduced its stake in GILD by selling 289 shares or 5.31% in the most recent quarter. The Hedge Fund company now holds 5,149 shares of GILD which is valued at $506,095. Gilead Sciences makes up approx 0.08% of Bkd Wealth Advisors’s portfolio.

On the company’s financial health, Gilead Sciences reported $3.03 EPS for the quarter, missing the analyst consensus estimate by $ -0.10 based on the information available during the earnings call on Apr 28, 2016. Analyst had a consensus of $3.13. The company had revenue of $7794.00 million for the quarter, compared to analysts expectations of $8065.42 million. The company’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.94 EPS.

Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Downgraded by Maxim Group to ” Hold” on Apr 29, 2016. Shares were Reiterated by UBS on Apr 29, 2016 to “Buy” and Lowered the Price Target to $ 118 from a previous price target of $130 .Shares were Reiterated by Leerink Partners on Mar 16, 2016 to “Outperform” and Lowered the Price Target to $ 127 from a previous price target of $130 .

Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Leave a Reply

Gilead Sciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Gilead Sciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.